Drug-coated balloon angioplasty for the treatment of edge stenosis after self-expanding covered stent placement for superficial femoral artery occlusive disease
Restricted accessResearch articleFirst published online February, 2021
Drug-coated balloon angioplasty for the treatment of edge stenosis after self-expanding covered stent placement for superficial femoral artery occlusive disease
Edge stenoses are the predominant limitation of self-expanding covered stent treatment of superficial femoral artery (SFA) occlusive disease, necessitating reinterventions. Angioplasty of an edge stenosis is associated with a high recurrence rate. Drug-coated balloon (DCB) treatment of edge stenoses might improve outcomes by decreasing the incidence of restenosis.
Purpose
The aim of this study was to evaluate the outcomes of using a DCB for the treatment of edge stenoses after self-expanding covered stent placement for SFA occlusive disease.
Method
We performed a retrospective analysis of patients treated with a DCB for edge stenoses after self-expanding covered stent placement. The primary endpoint was primary patency at one year. The secondary endpoints included procedure-related complications, secondary patency, and freedom from target lesion revascularization (TLR).
Results
A total of 21 patients with 28 edge stenoses were included. The time from primary treatment to treatment of the edge stenosis was 19 months (interquartile range (IQR) 8; 52 months). Primary patency and assisted primary patency at one year were 66.7% with a secondary patency of 90.9%. Freedom from TLR was 86.1%, and freedom from clinically driven TLR was 89.4%. Four patients presented with a hemodynamically significant restenosis, and three of those patients had an occlusion. Median time to failure was six months (IQR 3.5; 7.0 months), and median time to occlusion was four months (IQR 3.0; 6.0 months).
Conclusion
The treatment of edge stenoses using a DCB is associated with a safe one-year outcome; however, this has to be confirmed in larger prospective studies. The continuous surveillance of patients is indicated.
AboyansVRiccoJBBartelinkMEL, et al.
2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J2018;
39: 763–816.
2.
DickPWallnerHSabetiS, et al.
Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv2009;
74: 1090–1095.
3.
ChalmersNWalkerPTBelliA-M, et al.
Randomized trial of the SMART stent versus balloon angioplasty in long superficial femoral artery lesions: the SUPER study. Cardiovasc Intervent Radiol2012;
36: 353–361.
4.
StephanHDudaMBLammerJ, et al.
Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther2006;
13: 701–710.
5.
LairdJR, et al.
Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther2012;
19: 1–9.
6.
ScheinertDScheinertSSaxJ, et al.
Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol2005;
45: 312–315.
7.
LammerJZellerTHauseggerKA, et al.
Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial. Cardiovasc Intervent Radiol2015;
38: 25–32.
8.
McQuadeKGableDPearlG, et al.
Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease. J Vasc Surg2010;
52: 584–590; discussion 90-1, 91 e1-91 e7.
9.
ReijnenMvan WalravenLAFritschyWM, et al.
1-Year results of a multicenter randomized controlled trial comparing heparin-bonded endoluminal to femoropopliteal bypass. JACC Cardiovasc Interv2017;
10: 2320–2331.
10.
OhkiTKichikawaKYokoiH, et al.
Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions. J Vasc Surg2017;
66: 130–142.e1.
11.
GolchehrBHolewijnSKruseRR, et al.
Efficacy of treatment of edge stenosis of endografts inserted for superficial femoral artery stenotic disease. Catheter Cardiovasc Interv2015;
86: 492–498.
12.
LensveltMMAGolchehrBKruseRR, et al.
The outcome of failed endografts inserted for superficial femoral artery occlusive disease. J Vasc Surg2013;
57: 415–420.
13.
SaxonRRChervuAJonesPA, et al.
Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial. J Vasc Interven Radiol2013;
24: 165–173; quiz 74.
14.
JiaXZhangJZhuangB, et al.
Acotec drug-coated balloon catheter: randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the AcoArt I trial. JACC Cardiovasc Interven2016;
9: 1941–1949.
15.
ScheinertDSchmidtAZellerT, et al.
German center subanalysis of the LEVANT 2 global randomized study of the Lutonix drug-coated balloon in the treatment of femoropopliteal occlusive disease. J Endovasc Ther2016;
23: 409–416.
16.
XuYJiaXZhangJ, et al.
Drug-coated balloon angioplasty compared with uncoated balloons in the treatment of 200 Chinese patients with severe femoropopliteal lesions: 24-Month results of AcoArt I. JACC Cardiovasc Interven2018;
11: 2347–2353.
17.
BrodmannMWernerMMeyerDR, et al.
Sustainable antirestenosis effect with a low-dose drug-coated balloon: the ILLUMENATE European randomized clinical trial 2-year results. JACC Cardiovasc Interven2018;
11: 2357–2364.
18.
GerardiDAlfaniATesorioT, et al.
Drug-coated balloon in superficial femoral artery in-stent restenosis. Postep Kardio Inter2018;
14: 9–14.
19.
StabileEVirgaVSalemmeL, et al.
Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol2012;
60: 1739–1742.
20.
BagueNJuliaPSauguetA, et al.
Femoropopliteal in-stent restenosis repair: midterm outcomes after paclitaxel eluting balloon use (PLAISIR Trial). Eur J Vasc Endovasc Surg2017;
53: 106–113.
21.
VirgaVStabileEBiaminoG, et al.
Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up. JACC Cardiovasc Interv2014;
7: 411–415.
22.
LinTCHuangCYChenPL, et al.
Edge stenosis after covered stenting for long superficial femoral artery occlusive disease: risk factor analysis and prevention with drug-coated balloon angioplasty. J Endovasc Ther2018;
25: 313–319.
23.
StonerMCCalligaroKDChaerRA, et al.
Reporting standards of the Society for Vascular Surgery for endovascular treatment of chronic lower extremity peripheral artery disease. J Vasc Surg2016;
64: e1–e21.
24.
Rogers JH, Lasala JM. Coronary artery dissection and perforation complicating percutaneous coronary intervention. J Invasive Cardiol 2004; 16(9): 493–499.
25.
Anantha-NarayananMShahSMJelaniQU, et al.
Drug-coated balloon versus plain old balloon angioplasty in femoropopliteal disease: an updated meta-analysis of randomized controlled trials. Catheter Cardiovasc Interv2019;
94: 139–148.
26.
KinstnerCMLammerJWillfort-EhringerA, et al.
Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-year results of the PACUBA trial. JACC Cardiovasc Interv2016;
9: 1386–1392.
27.
KrankenbergHTublerTIngwersenM, et al.
Drug-coated balloon versus standard balloon for superficial femoral artery in-stent restenosis: the randomized femoral artery in-stent restenosis (FAIR)trial. Circulation2015;
132: 2230–2236.
28.
GolchehrBFritschyWMHolewijnS, et al.
Outcome of thrombolysis and thrombectomy for thrombosed endografts inserted in the superficial femoral artery for occlusive disease. J Endovasc Ther2013;
20: 836–843.
29.
SalisburyACLiHVilainKR, et al.
Cost-effectiveness of endovascular femoropopliteal intervention using drug-coated balloons versus standard percutaneous transluminal angioplasty: results from the IN.PACT SFA II trial. JACC Cardiovasc Interv2016;
9: 2343–2352.
30.
KatsanosKSpiliopoulosSKitrouP, et al.
Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc2018;
7: e011245.
31.
SchneiderPALairdJRDorosG, et al.
Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Cardiol2019;
73: 2550–2563.
32.
BehrendtCASedrakyanAPetersF, et al.
Long term survival after femoropopliteal artery revascularisation with paclitaxel coated devices: a propensity score matched cohort analysis. Eur J Vasc Endovasc Surg2020;
59: 587–596.
